SubHero Banner

Truvada® (emtricitabine/tenofovir disoproxil fumarate) – Expanded indication

May 15, 2018 - The FDA announced the approval of Gilead’s Truvada (emtricitabine [FTC]/tenofovir disoproxil fumarate [TDF]), in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually active human immunodeficiency virus type 1 (HIV-1) in at-risk adolescents weighing at least 35 kg.

Download PDF